期刊文献+

联合降压治疗糖尿病合并高血压病疗效分析 被引量:1

Analysis on Effect of Combination Depressurization Therapy in Diabetes Combined with Hypertension
原文传递
导出
摘要 目的:探讨联合应用降压药治疗2型糖尿病合并高血压临床疗效。方法:采取随机分组平行分组对照方法,将患者分为两组,A组29例,单用硝苯地平缓释片40 mg/d;B组29例,硝苯地平缓释片20 mg/d+缬沙坦(血管紧张素Ⅱ受体阻滞剂,ARB)80 mg/d。结果:治疗8周后,B组收缩压(SBP)<130 mm Hg和舒张压(DBP)<80 mm Hg,达标率分别为68.96%和93.10%,较A组明显增高(P<0.05),不良反应少(P<0.05)。结论:钙拮抗剂联合ARB治疗2型糖尿病合并高血压疗效理想,且不良反应低。 Objective:To explore the clinical effects of combination depressurization therapy in patients with type 2 diabetes combined with hypertension. Methods:The patients were divided into two groups ( A and B) by random allocation and parallel-group control method. The patients in group A received nifedipine sustained-- released tablets 40 mg/d single,and the patients in group B received nifedipine sustained-released tablets 20 mg/d and valsartan(ARB)80 mg/d. Results: After treatment for 8 weeks, SBP〈130 mm Hg and DBP〈80 mm Hg of patients in group B. The normal rates of SBP and DBP of patients were 68.96% and 93.10% respectively. There was a significantly increases in group B than group A( P〈0.05), and there was a less adverse reaction in group B( P〈0.05 ). Conclusions:There is an ideal curative effects and a less adverse reactionin treatment of type 2 diabetes combined with hypertension with ARB.
出处 《中国误诊学杂志》 CAS 2010年第7期1531-1532,共2页 Chinese Journal of Misdiagnostics
关键词 糖尿病/并发症 高血压/并发症/药物疗法 硝苯地平/治疗应用 四唑类/治疗应用 缬氨酸/类似物和衍生物 缬氨酸/治疗应用 Diabetes/complication Hypertension/complication/drug therapy Nifedipine/therapeutic use Tetrazoles/therapeutic use Valine/therapeutic use
  • 相关文献

参考文献5

二级参考文献12

  • 1Guidelines.Subcommittee of the World Health Organization-International Society of Hypertension(WHO/ISH) Mild Hypertension Liason Committee.1999 World Health Organization-International.Society of Hypertension guidelines for the management of hypertension.J Hypertens,1999,17(2):151-183 被引量:1
  • 2Devereux RB,Alonso DR,Lutas EM,et al.Echocardiographic assessment of left ventricular hypertrophy:comparison to necropsy findings[J].Am J Cardiol,1986,57(6):450-458 被引量:1
  • 3Criscione L,De Gasparo M,Buhlmayer P,et al.Pharmaclogical profile of valsartan:a potent,orally active,nonpeptide antagonist of thangiotensin Ⅱ AT1 receptor subtype.Br J Pharmacol,1993,110(2):761-771 被引量:1
  • 4Yamada T,Horiuchi M,Dzau VJ.Angiotensin Ⅱ type 2 receptor mediates programmed cell death.Proc Natl Acad Sci USA,1996,93(1):156-160 被引量:1
  • 5Morice AH,Brown MJ,Higenbottam T,Cough associated with angiotensin with angiotensin converting enzyme inhibition.J Cardiovasc Pharmacol,1989,13(supp 3):59-62 被引量:1
  • 6Sowers JR,Epstein M.Diabetes mellitus and associated hypertension,vascular disease,and nephropathy:an update[J].Hypertension,1995,26(8):869-879. 被引量:1
  • 7Chobanian AV,Bakris GL,Black HR,et al.Seventh Report of the joint National Committee on prevention,Detection,Evaluation,and Treatment of High Blood Pressure[J].JAMA,2003,289(12):2560-2571. 被引量:1
  • 8Grundy,Scott M,Cleeman,et al.Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines[J].Circulation,2004,110(5):227-239. 被引量:1
  • 9曹云峰 梁江红.经颅多普勒超声对糖尿病血管病变的血流动力学评价.中国超声医学杂志,2000,16(5):349-349. 被引量:3
  • 10Rosa EM,Kramer C.Castolassociation between coronary arteryather artery atherosclerosis and the intima media thickeness of the common carotid artery measured on ultrasonography[J].Arg Bras Cardiol,2003,80(6):589-592. 被引量:1

共引文献15

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部